Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib + letrozole versus EC followed by docetaxel as neoadjuvant therapy for inoperable postmenopausal ER-positive low-Ki67 breast cancer
ChiCTR1900026493Phase 4Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Dec 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in breast cancer comparing Palbociclib + letrozole with Epirubicin + cyclophosphamide followed by docetaxel (2 arms). Primary endpoint: Efficacy. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
palbociclibletrozoleepirubicincyclophosphamidedocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900026493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026493.